SCYX - Scynexis shares up 5% on positive ibrexafungerp data in fungal infections

Scynexis (SCYX) perks up 6% premarket on positive results from the interim efficacy analysis of Phase 3 FURI study and Phase 3 CARES study. In FURI study, antifungal activity was consistently positive across all interim analyses with oral ibrexafungerp showing clinical benefit in 30 out 33 patients, and no patient with progression of disease.Clinical benefits were seen in 86.5% of patients (64 out 74), with 46 patients achieving a complete or partial response and 18 achieving a stable disease response.Analysis of the CARES study found that 80% (8 out 10) patients with invasive candidiasis and candidemia, due to C. auris, experienced a complete response, and one patient died of an underlying condition unrelated to the treatment and one patient was considered indeterminate. Oral ibrexafungerp exhibited a positive safety profile and was well-tolerated.Each study is intended to support a potential future NDA submission. The company will hold a conference call today at 8:30 a.m.

For further details see:

Scynexis shares up 5% on positive ibrexafungerp data in fungal infections